Have any questions? 706-721-6582 or cts@augusta.edu
- A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
Clinical Trial
A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
This is a study to look at how safe and effective the study drug is in people with Cognitive Impairment Associated with Schizophrenia (CIAS). CIAS refers to some issues that people with schizophrenia may have, including having trouble remembering things, paying attention, learning new things, or making good decisions.
Eligibility Criteria
- Inclusion Ages 18-55 Capable of giving informed consent Current diagnosis of Schizophrenia Currently perscribed an atypical antipsychotic Exclusion History of seizures Significant head injuries with loss of consciousness more than 15 minutes
RESEARCH. INNOVATION. DISCOVERY.